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Abstract 
The dimeric peptide 1 (BVD-74D, as a diastereomeric mixture) is a potent and selective 
Neuropeptide Y Y4 receptor agonist. It represents a valuable candidate in developing 
traceable ligands for pharmacological studies of Y4 receptors, and as a lead compound for 
anti-obesity drugs. Its optically pure stereoisomers along with analogues and fluorescently 
labelled variants were prepared by exploiting alkene metathesis reactions. The (2R,7R)- 
diaminosuberoyl containing peptide, (R,R)-1 had markedly higher affinity and agonist 
efficacy than its (S,S)-counterpart. Furthermore the sulfo-Cy5 labelled (R,R)-14 retained high 
agonist potency as a novel fluorescent ligand for imaging Y4 receptors. 
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Introduction 
The physiological functions of three polypeptides that form the NPY peptide family, 
neuropeptide Y (NPY)1 and peptide YY (PYY),2 and pancreatic polypeptide (PP),3 are 
mediated by Y receptors, where four subtypes have been identified in human: Y1R, Y2R, Y4R 
and Y5R. All subtypes belong to the rhodopsin-like Gi coupled G-protein coupled receptor 
(GPCR) superfamily.4 These Y receptor subtypes exhibit different binding affinity to the 
three members of NPY peptide family. It was found that Y1R and Y2R exhibit similar affinity 
to NPY and PYY, but poor affinity to PP. Y4R is a PP-selective subtype with lower affinity 
for NPY and PYY. Lastly, all three peptides are equally potent at Y5R.
5 
Activation of the PP/Y4R signalling system induces satiety and promotes energy expenditure. 
This suggests that Y4R agonists may become clinically useful anti-obesity drugs, while Y4R 
antagonists may have potential as orexigenic agents to treat anorexia.6-9 In developing such 
ligands, truncated peptide analogues are becoming increasingly popular. For example, 
[Nle30]hPP25-36 and [Leu
34]pNPY25-36 were found to be Y4R selective partial agonists,
10 and a 
nonapeptide based on the C-terminal fragment of NPY, Ile-Asn-Pro-Ile-Tyr-Arg-Leu-Arg-
Tyr-NH2 exhibits moderate Y4R agonism and Y1R competitive antagonism with similar 
potency.11-13 Its lactam-bridged dimeric variant bis(29/31’, 29/31’)[(Glu29, Pro30, Dpa31, 
Tyr32, Leu34)NPY28-36], also known as 1229U91, showed enhanced potency at both receptor 
subtypes but is in particular the most potent known Y1R antagonist.
13-17 
Another of several highly potent Y receptor ligands based upon dimeric C-terminal 
sequences is D/L-2,7-diaminooctanedioyl-bis(YRLRY-NH2), 1 (BVD-74D)
18 (Figure 1). 
This peptide exhibited comparable Y4R affinity with the native hPP (Ki = 0.05 nM vs. 0.08 
nM) and showed 150-fold selectivity for Y4R over Y1R, and negligible affinity to Y2R and 
Y5R. In fasted rat subjects, 1 showed equally potent inhibitory effects on food intake as the 
endogenous PP.18 A later study also reported that 1 significantly reduced food intake, water 
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intake and weight gain in mice fed with normal and high-fat diet.19 However, the reported 
compound is, in fact, a mixture of diastereomers composed of the (2S,7S)- and (2R,7R)-
diaminooctanedioyl-containing stereoisomers,18 and they are inseparable by RP-HPLC. 
Therefore it was unclear which stereoisomer contributed to the in vitro and in vivo 
pharmacological activity.  
 
Figure 1: The BVD-74D peptide 1 reported by Balasubramaniam et al. is a diastereomeric mixture of the 
(2S,7S)- and (2R,7R)-diaminooctanedioyl stereoisomers. 
We aimed to resolve this issue, and set a platform for the broader investigation of Y4R 
pharmacology by the synthesis of optically pure stereoisomers of 1 and related analogues that 
probe the role of the bridging group and the role of the dimeric structure in facilitating high 
affinity. We hereby present our work on synthesis of a series of optically pure analogues of 
(S,S)-1 and (R,R)-1 along with their fluorescently labelled variants. We developed 
methodology for preparing the dimeric peptides utilising Grubbs metathesis, either in the 
synthesis of optically pure 2,7-diaminosuberic acid building blocks or the on resin metathesis 
of monomeric precursor peptides.20-22 Those peptide analogues were analysed using cell 
based Y4R competition binding assays and β-arrestin recruitment assays to identify the (R,R)-
diastereomers as the high affinity constituent of 1 and the corresponding fluorescent 
analogues. 
Results and Discussion 
Chemistry 
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The main challenge in developing a convenient and robust strategy for synthesising optically 
pure dimeric 1 analogues was to identify an optimal condition for metathesis reactions. Two 
different approaches were attempted. The first approach involved pre-synthesis of the 2,7-
diaminosuberic acid unit then bis-coupling to the linear peptidyl-resin, while the second 
involved a solid phase cross-metathesis between two completed linear N-terminal 
allylglycine containing peptides. 
Synthesis of (S,S)-1 and (R,R)-1 
The synthesis of (2S,7S)-N,N-di-Boc-diaminosuberic acid23 (2S,7S)-5 via metathesis was 
achieved by adapting the methods of Nolen et al.24 and Ward et al.25 (Scheme 1) The (S)-N-
Boc-allylglycine methyl ester (2) was treated with Grubbs catalyst 2nd generation in refluxing 
DCM overnight to obtain the desired alkene 3 in 95% yield. The intermediate 3 was then 
hydrogenated in presence of 10% Pd/C, which gave 4 almost quantitatively. Finally, the 
desired product (2S,7S)-5 was generated by ester hydrolysis. Spectroscopic data for (2S,7S)-5 
were consistent with that previously reported,23 including the determined (-) optical rotation 
in DMF.26 Experimental details are provided in Supporting Information. 
 
Scheme 1: Synthesis of (2S,7S)-N,N-di-Boc-diaminosuberic acid (2S,7S)-5. Reagents and 
conditions: a. Grubbs catalyst 2nd generation, DCM, reflux, overnight, 95%; b. 10% Pd/C, 
MeOH, H2, RT, overnight; c. NaOH in H2O (6 mg/ml), MeOH, reflux, overnight, 50% (from 
3). 
To prepare the (2R,7R)-N,N-di-Boc-diaminosuberic acid, (2R,7R)-5, we investigated the use 
of 1,3-benzenedimethanol as a “template” to enable selective ring-closure metathesis as 
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reported by previously.27, 28  Esterification of Boc-D-allylglycine-OH (6) gave the diester 7 
which was a substrate for RCM, and gave 8 in 54% yield. Finally one-pot reduction and 
hydrogenolysis of 8 was achieved by treating with hydrogen in the presence of 10% Pd/C 
affording (2R,7R)-5. Polarimetry confirmed the expected (+) optical rotation of the 
precursor.26 
 
Scheme 2: Synthesis of (2R,7R)-N,N-di-Boc-diaminosuberic acid, (2R,7R)-5. Reagents and 
conditions: a. benzenedimethanol, EDCI, DMAP, DCM, RT, overnight, 56%; b. Grubbs 
catalyst 2nd generation, DCM, N2, reflux, overnight, 54%; c. 10% Pd/C, MeOH, 1 atm H2, 
53%. 
To further confirm the chiral integrity of the products, a chiral HPLC method was developed 
that showed that preparation of (2S,7S)-5 and (2R,7R)-5 was not accompanied by significant 
racemization either to each other or to the meso (2R,7S)-529 in these syntheses (see 
Supporting Information).  
Having the protected building blocks in hand, dimeric peptide analogues (S,S)-1 and (R,R)-1 
were prepared by conventional solid phase peptide synthesis (Scheme 3). After constructing 
the linear peptide chain on Rink amide resin, the coupling was carried out using 0.5 
equivalents of the Boc-protected 2,7-diaminosuberic acid (S,S)-5 or (R,R)-5 activated with 
PyClock and overnight incubation. After cleavage, the desired peptides were obtained and 
readily purified by RP-HPLC.  
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Scheme 3: Synthesis of (S,S)-1 using pre-synthesised (2S,7S)-N,N-di-Boc-diaminosuberic 
acid 5. Reagents and conditions: a. (2S,7S)-5, PyClock, DIPEA, DMF, RT, overnight; b. 
Reagent K, RT, 3 h.  
As an alternative approach, the synthesis of dimeric peptides was achieved by solid phase 
cross-metathesis of the corresponding resin-bound protected allylglycine containing peptides. 
(Scheme 4) The monomeric peptide chain containing either L- or D-allylglycine was first 
assembled following the standard Fmoc-based solid phase synthesis strategy, where the N-
terminal Fmoc group was retained. The peptidyl-resin was then subject to cross-metathesis by 
treating with Grubbs catalyst 2nd generation under deoxygenated conditions and microwave 
heating in presence of LiCl as a chaotropic salt.21 Fmoc deprotection followed by cleavage 
yielded the alkenyl peptides, (S,S)-9 and (R,R)-9. 
The synthesis of (R,R)-1 was also achieved by hydrogenation of (R,R)-9 in presence of 10% 
Pd/C in EtOAc (Scheme 4). While successful and operationally straightforward, the yield and 
purity of the crude peptide product was not as good as the same peptide made from pre-
synthesised diaminosuberic acids as described above. 
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Scheme 4: Synthesis of dimeric peptides (R,R)-9 and (R,R)-1 via solid phase metathesis 
reaction. Reagents and conditions: a. Grubbs catalyst 2nd generation, LiCl in DMF, DCM, 
µwave 100˚C, 3 h; b. piperidine (20%) in DMF, RT, 5 min×2; c. Reagent K, RT, 3 h; d. Pd/C 
cartridge, H2
 (50 psi), EtOAc, 50˚C, 1 h. 
Synthesis of homo- and hetero-dimeric methyl esters of (S,S)-1 
Having established efficient strategies for preparation of dimeric analogues with specified 
stereo-configuration, we investigated the role of the C-terminal amides in Y4R interaction by 
replacing them as mono- or di-methyl esters. Our strategy was to utilise side-chain anchoring 
to the resin to allow manipulation of the terminal carboxylate. Peptide anchoring to resin via 
the side-chain of tyrosine esters has been described on both benzyl-type resins30 and 2-
chlorotrityl chloride resin.31 
We first prepared the free phenolic tyrosine derivatives, Fmoc-Tyr-OMe (10)32 and Fmoc-
Tyr amide (11)33(see Supporting Information). The di-methyl ester (S,S)-12 was achieved by 
coupling 10 to 2-chlorotrityl chloride resin via the phenol group.31 The remainder of the 
peptide sequence was assembled as described above with final coupling of (2S,7S)-5 and 
standard acidolytic cleavage (Scheme 5). 
To synthesise the heterodimeric mono-methyl ester (S,S)-13, 10 and 11 were anchored 
simultaneously to 2-chlorotrityl chloride resin as a 1:1 mixture. Standard SPPS was continued 
as described above and final coupling of (2S,7S)-5 was followed by standard cleavage. The 
products were an approximately 2:1:1 mixture of the desired heterodimer (S,S)-13 and the 
homodimers, the di-amide (S,S)-1 and di-methyl ester (S,S)-12 (Scheme 5). The three major 
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peptide products were readily resolved by RP-HPLC allowing isolation of the desired 
product. Notable in the syntheses of compounds (S,S)-12 and (S,S)-13 was an excellent 
recovery of peptide products, indicative of more efficient cleavage from the 2-chlorotrityl 
chloride resin than from Rink Amide resin. 
 
Scheme 5: Synthesis of peptides (S,S)-12 and (S,S)-13. Reagents and conditions: a. 2-
chlorotrityl chloride resin, DIPEA, DCM, RT, overnight; b. standard solid phase synthesis; c. 
5, PyClock, DIPEA, DMF, RT, overnight; d. Reagent K, RT, 3 h. 
 
Synthesis of fluorescently labelled diastereomers of (S,S)-1 and (R,R)-1 
In order to develop fluorescently labelled Y4R-targeting ligands for in vitro Y4R studies, 
(S,S)-1, (R,R)-1, (S,S)-II and (R,R)-II were conjugated with either a rhodamine B (RhB) 
derivative34 or the commercially available sulfo-Cy5 (sCy5) dye (Figure 2). Following our 
previously reported methods for mono-conjugation of dimeric peptides,35 peptides (S,S)-1 
and (R,R)-1 were treated with 0.7 molar equivalents of sCy5 in presence of PyClock and 
DIPEA to give the desired mono-labelled analogues (S,S)-14 and (R,R)-14 respectively after 
purification, and peptides (S,S)-1, (S,S)-9 and (R,R)-9  treated with the rhodamine B 
derivative to give (S,S)-15, (S,S)-16 and (R,R)-16 respectively (Scheme 6). 
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Figure 2: The structures of carboxy derivatised fluorophore reagents used: sulfo-Cy5 (sCy5) 
and rhodamine B (RhB). 
 
Scheme 6: Example of fluorophore conjugation of (S,S)-1. Reagents and condition: sCy5 or 
RhB (0.7 eq.), PyClock, DIPEA in DMF, RT, overnight. 
In summary, we have successfully developed unambiguous synthetic routes to prepare 
optically pure 1 and analogues through both solution and solid phase alkene metathesis 
reactions. Mono-labelled fluorescent analogues were conveniently prepared by standard 
solution phase coupling using limited molar equivalents of fluorophores. Utilising these 
strategies, 11 dimeric analogues were prepared and their analytical data are summarised in 
Table 1. 
Table 1: Synthesised dimeric peptides and their analytical data. 
Code Sequence a ESI-MS b HPLC RT.c 
(min) 
(S,S)-1 (2S,7S)-sub(YRLRY-NH2)2  569.75 11.21 
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(R,R)-1 (2R,7R)-sub(YRLRY-NH2)2  569.85 11.16 
(S,S)-9 (2S,7S)-∆sub(YRLRY-NH2)2 569.05 11.19 
(R,R)-9 (2R,7R)-∆sub(YRLRY-NH2)2 569.10 11.34 
(S,S)-12 (2S,7S)-sub(YRLRY-OMe)2 579.85 12.06 
(S,S)-13 (2S,7S)-sub(YRLRY-NH2)(YRLRY-OMe) 574.85 11.61 
(S,S)-14 mono-sCy5-(2S,7S)-sub(YRLRY-NH2)2 782.70 12.38 
(R,R)-14 mono-sCy5-(2R,7R)-sub(YRLRY-NH2)2 782.75 12.36 
(S,S)-15 monoRhB-(2S,7S)-sub(YRLRY-NH2) 767.40 13.37 
(S,S)-16 monoRhB-(2S,7S)-∆sub(YRLRY-NH2)2 766.65 13.36 
(R,R)-16 monoRhB-(2R,7R)-∆sub(YRLRY-NH2)2 766.70 13.26 
a. Sub = 2,7-diaminosuberoyl linkage; ∆sub = 2,7-diaminooctene-4-dioyl linkage. 
b. ESI-MS base peak corresponds to [M+3H]3+. 
c. HPLC retention time using a Phenomenex Luna C-8 column (100Å, 3µm, 
100×2.00mm). The gradient is composed of 100% H2O (0.1% TFA) for 4 min, 0-60% 
acetonitrile in H2O (0.1% TFA) over 10 min, and isocratic 60% acetonitrile in H2O 
(0.1% TFA) for 1 min. 
Pharmacology 
The pharmacological characteristics of these dimeric peptides were assessed by receptor 
binding and functional assays using whole cell assay systems. This enabled binding to be 
assessed in physiological buffer in cells (expressing human Y4R tagged with green 
fluorescent protein, GFP) rather than membranes, to provide equivalence with subsequent 
functional measurements.  
Y4R binding affinity data were obtained by competition binding against the sCy5-labelled 
peptide 17, ([Lys2(sCy5),Arg4]BVD-15, 100 nM), analysed on a high content imaging 
platereader (Table 2, Figure 3).36, 37 The endogenous reference ligand, human PP, showed 
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nanomolar affinity (IC50 = 2.31 nM) in this assay. Of all the peptides, (2R,7R)-1 exhibited the 
highest Y4R affinity (IC50 = 12.7 nM), and was 5.5-fold higher in affinity than (2S,7S)-1. 
 
Table 2: Synthesised dimeric peptides and their pharmacological data. 
Code Sequence 
a 
pIC50 
b 
Rmax 
c
 (% 
100 nM PP) 
pEC50 
d
 
PP  8.64±0.12 96.3±4.0 8.58±0.10 
(S,S)-1 (2S,7S)-sub(YRLRY-NH2)2  7.16±0.10 57.1±10.9 7.08±0.30 
(R,R)-1 (2R,7R)-sub(YRLRY-NH2)2  7.90±0.10 61.5±0.17 8.33±0.17 
(S,S)-9 (2S,7S)-∆sub(YRLRY-NH2)2 6.88±0.09 44.5±4.8 7.52±0.20 
(R,R)-9 (2R,7R)-∆sub(YRLRY-NH2)2 7.62±0.11 61.0±5.2 7.42±0.15 
(S,S)-12 (2S,7S)-sub(YRLRY-OMe)2 6.21±0.11 11.3±6.7
d N.D. 
(S,S)-13 (2S,7S)-sub(YRLRY-NH2)(YRLRY-OMe) 7.03±0.10 49.1±6.8 <6.5 
(S,S)-14 mono-sCy5-(2S,7S)-sub(YRLRY-NH2)2 N.D. 56.6±11.8 7.02±00.33 
(R,R)-14 mono-sCy5-(2R,7R)-sub(YRLRY-NH2)2 N.D. 65.6±5.7 7.48±0.16 
(S,S)-15 monoRhB-(2S,7S)-sub(YRLRY-NH2) 7.15±0.09 15.9±9.1
d N.D. 
(S,S)-16 monoRhB-(2S,7S)-∆sub(YRLRY-NH2)2 7.16±0.10 29.2±4.6 8.26±0.37 
(R,R)-16 monoRhB-(2R,7R)-∆sub(YRLRY-NH2)2 7.15±0.09 39.3±4.2 8.43±0.26 
a. Sub = 2,7-diaminosuberoyl linkage; ∆sub = 2,7-diaminooctene-4-dioyl linkage  
b. Derived from competition binding assays using 100 nM 17 as the fluorescent ligand. 
c. From Y4R-β-arrestin2 recruitment assays.  
d. In the absence of significant agonist activity, the effect at 1 µM peptide is reported.  N.D. 
= not determined 
The remaining analogues examined here have not been previously described (Table 2).  In the 
alkenyl dimer series, a preference for the (R,R)-9 was again observed compared to the (S,S)-
diastereomer, but overall these compounds showed 2- to 3-fold lower affinity for Y4R than 
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the corresponding diaminosuberic linked analogues 1. It can be concluded that 
conformational restraint due to the presence of the alkene group is not favoured. Substitution 
of one C-terminal amide (S,S)-13 for an ester moiety did not lead to a major loss of Y4R 
affinity compared to the corresponding diamide (S,S)-1 in these assays. However, 
replacement of both amides as in compound (S,S)-12, has a major impact with an order of 
magnitude drop in affinity. Mono N-terminal modification of (R,R)-9 with rhodamine B 
giving (R,R)-16 led to a 3-fold reduction in affinity, but rhodamine B addition was well 
tolerated in analogues (S,S)-15 and (S,S)-16. The three rhodamine B containing peptides had 
essentially overlapping competition curves. 
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Figure 3: Y4R competition binding assays using high content imaging. A. 293TR Y4-GFP 
cells were incubated with 100 nM, 17 in the absence (control) or presence of increasing 
concentrations of stereoisomers of 1.  Following 30 min at 37°C, Y4-GFP and fluorescent 
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ligand images were acquired on an IX Ultra platereader. The panels show 400×400 regions of 
interest from the 1000×1000 pixel original plate images; scale bar 50 µm. B. Specific binding 
of 17 was quantified and normalised using granularity analysis as described in the methods, 
to obtain competition curves for peptide analogues synthesised in the current study. Graphs 
show pooled competition data (n = 5), from which the pIC50 values in Table 2 were 
determined.  
The selectivity of  representative peptides (R,R)-1, (S,S)-9 and (S,S)-12 was measured by 
Y1R-GFP whole cell competition binding (using the same fluorescent ligand 17 (10 nM), and 
confirmed at least 30-fold selectivity of representative for Y4R over Y1R, the Y receptor 
subtype most closely related in amino acid homology.38 Y1R pIC50 values were 6.44±0.14, 
6.31±0.30 and 6.63±0.12 for analogues (R,R)-1, (S,S)-9 and (S,S)-12 respectively (n = 3). 
The functional Y4R agonism produced by the peptides was analysed using a β-arrestin2 
recruitment assay to detect Y4R activation (Figure 4), as previously described.
39, 40 One 
advantage of this assay is its limited receptor reserve, which improves correspondence 
between agonist potency (as EC50, the concentration of agonist that produces 50% of its 
maximal response) and underlying functional receptor affinities, and also the likelihood that 
differences in agonist intrinsic efficacy are revealed through changes in relative maximum 
response (Rmax).
41  Thus the reference agonist human PP stimulated β-arrestin2 association 
with an EC50 value (2.6 nM) very similar to its derived pIC50 in the whole cell Y4R binding 
experiments. 
Compared to PP, all the peptides were partial agonists in the Y4R-arrestin recruitment assays, 
with typical Rmax values 44-62% of that of PP (Table 2). The order of potency broadly 
reflected binding data in that (i) (R,R)-1 (EC50 = 4.6 nM) was 20-fold more potent than the 
(S,S)-1, (Figure 4A), (ii) the alkenyl derivatives (R,R)-9 and (S,S)-9 were less potent overall 
than the dimers with saturated linkages (Figure 4B) and (iii) replacement of one or both C-
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terminal amides with ester moieties, (S,S)-13 and (S,S)-12 respectively, resulted in a loss of 
potency and efficacy (Figure 4B). 
The functional assay enabled assessment of both RhB- and sCy5-labelled analogues as Y4R 
agonists. In general, maximum responses to rhodamine analogues were reduced compared to 
the respective parent compounds, with compound (S,S)-15 (RhB derivative of (S,S)-1) being 
without significant effect in the assay (Table 2). In contrast, mono-labelling with sCy5 as in 
(S,S)-14 and (R,R)-14, preserved the same level of maximal response exhibited by their 
parent peptides (Figure 4C). The sCy5-labelled (R,R)-14 was more potent, with an EC50 value 
(34 nM) approximately 7-fold lower potency than (R,R)-1. 
 
Figure 4:  Y4R agonism as assessed in the Y4R β-arrestin2 recruitment assay. The HEK293 
Y4 β-arrestin2 BiFC cell line was stimulated for 60 min with human PP or synthesised 
compounds, and the development of complemented YFP fluorescence following Y4R 
activation was imaged and quantified using granularity analysis. Panels A-C represent pooled 
data (n = 4 or greater), normalised to the 100 nM PP response, from which pEC50 and Rmax 
values were estimated (Table 2).  
The sCy5 derivatives (S,S)-14 and (R,R)-14 were explored further for their properties as 
novel Y4R fluorescent ligands. Both compounds labelled Y4R-GFP expressing 293TR cells in 
a concentration dependent manner (with (R,R)-14 more potent), dependent on prior induction 
of receptor expression via tetracycline pretreatment (Figure 5). As anticipated for a ligand 
with agonist properties, both surface and intracellular distribution of sCy5 fluorescence was 
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observed, likely reflecting some co-internalisation of Y4R ligand complexes from the plasma 
membrane following receptor activation. The presence of increasing concentrations of PP 
competed for the binding of (S,S)-14 or (R,R)-14.  
To confirm the utility of (R,R)-14 in competition binding experiments, the fluorescence 
spectrum in physiological buffers was determined and found the lambda max to be the same 
as that of the underivatised sCy5-NHS dye (absorption max 656 nm, emission max 665 nm) 
with a relative quantum yield of 31% (see Supporting Information). We then used (R,R)-14 to 
label cells with 100 nM (R,R)-14, and determined the PP pIC50 was 8.36±0.09 (IC50 = 4.31 
nM, n = 3), consistent with the IC50 obtained using 17 (see Table 2). 
The collected assay data from these studies raise interesting questions regarding the 
molecular mechanism governing the high potency of peptide (R,R)-1  as compared to other 
analogues, and therefore how dimeric analogues impart enhanced affinity generally. Set 
against recent studies of the Y4R-hPP interaction,
42 the simplest model is that the “first arm” 
of the dimer binds the receptor in the canonical fashion while the “second arm” contributes to 
the affinity, perhaps by mimicry of the hPP helical region 14-30. An alternate view might be 
that the ligand binding is driven by the doubling of the local concentration of the C-terminal 
binding motif. The influence of the flexible bridging ligand argues against this latter 
explanation although the clear preference for the presence of the (R,R)-configuration may 
imply a preference for a D-amino acid at that position of the truncated peptide that has not 
been tested in other analogues. The comparable affinity of (S,S)-1 and the half ester, half 
amide (S,S)-13  may also suggest that the two arms play different roles in receptor binding, 
where in the “second arm” the C-terminal carboxamide is not so critical. The development of 
synthetic routes to further interrogate the structure-activity of stereochemically defined 
homo- and heterodimers suggests a great opportunity for the much needed development of 
Y4R ligands. 
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Figure 5: sCy5 labelled peptides as fluorescent Y4R ligands. Representative images show 
binding and localisation of mono-sCy5 labelled (S,S)-14 (300 nM) or (R,R)-14 (100 nM) 
following 30 min pre-incubation with 293TR Y4GFP cells. Panels illustrate the lack of 
fluorescent ligand binding in controls cells without Y4R protein expression induced by 
tetracycline treatment (No Tet), or in the presence of competing ligand (1 µM PP). Examples 
are magnified regions of individual IX Ultra images, as described for Figure 4, representative 
of 3 independent experiments. Scale bar 50 µm.  
Conclusion 
Pharmacological observations support the conclusion that the (R,R)-1 is the active principle 
of the original mixture of diastereomers 1, and as for the native peptides, C-terminal 
amidation of these compounds is required for Y4R agonist activity. As previous fluorescent 
ligand SAR studies have indicated,43, 44 the choice of rhodamine or sCy5 fluorophore 
influences the result Y4R properties of the labelled compounds, with mono-sCy5 labelled 
derivative (R,R)-14 being identified as a novel nanomolar affinity fluorescent Y4R agonist. 
Experimental Section 
Materials 
Nα-Fmoc and Nα-Boc protected amino acids were purchased from Auspep, Chemimpex and 
Mimotopes. Unless otherwise specified, all amino acids used were of L-conformation. Rink 
amide resin (0.53 meq/g, 100-200 mesh), 2-chlorotrityl chloride resin (1.12 meq/g, 200-400 
mesh), HCTU and PyClock were obtained from Chemimpex. TFA was purchased from Alfa 
Aesar. Thioanisole, 1,2-ethanedithiol, DIPEA, piperidine, Boc anhydride, triethylamine, 
EDCI, DMAP, 1,3-benzenedimethanol, Fmoc-OSu, pyridine, 1,4-dioxane and Grubbs 
catalyst 2nd generation were purchased from Sigma-Aldrich. Phenol, chlorotrimethylsilane 
and all solvents were obtained from Merck. The sCy5 fluorescence probe was purchased 
from W&J PharmaChem. The Rhodamine B analogue was purchased from Sigma-Aldrich 
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and modified as reported.34 All solvents were of analytical grade, and all chemicals were used 
without further purification.  
Molecular mass of the compounds were determined by ESI-MS using a Shimadzu 
LCMS2020 instrument, incorporating a Phenomenex Luna C-8 column (100Å, 3µm, 
100×2.00mm). This system used 0.05% TFA in MilliQ water as the aqueous buffer, and 
0.05% TFA in acetonitrile as the organic buffer. The eluting profile was a linear gradient of 
0-60% acetonitrile in water over 10 min at 0.2 ml/min. 
HRMS analyses were carried out on an Agilent 6224 TOF LC/MS Mass Spectrometer 
coupled to an Agilent 1290 Infinity (Agilent, Palo Alto, CA). All data were acquired and 
reference mass corrected via a dual‐spray electrospray ionisation (ESI) source. Acquisition 
was performed using the Agilent Mass Hunter Data Acquisition software version B.05.00 
Build 5.0.5042.2 and analysis was performed using Mass Hunter Qualitative Analysis version 
B.05.00 Build 5.0.519.13. 
Crude peptides were purified on a Phenomenex Luna C-8 column (100Å, 10µm, 
250×21.2mm) utilising a Waters 600 semi-preparative RP-HPLC that incorporates a Waters 
486 UV detector. The wavelength was set at 230 nm. This system used 0.1% TFA in MilliQ 
water as the aqueous buffer, and 0.1% TFA in acetonitrile as the organic buffer. The eluting 
profile was a linear gradient of 0-80% acetonitrile in water over 60 min at 10 ml/min. 
Peptide synthesis 
The purity of all reported peptides are ≥ 95% according to the HPLC chromatographs 
produced by the ESI-MS method described above.  
General synthesis 
Linear peptide chains were synthesised on Rink amide resin or 2-chlorotrityl chloride resin 
(sequence dependent) using a 3-channel serial automated peptide synthesiser (“PS3”, Protein 
Technologies Inc.), which adopted standard Fmoc-based solid phase synthesis strategy. Fmoc 
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deprotection was performed by 20% v/v piperidine in DMF for 2×5 min. Fmoc protected 
amino acids (3 eq.) were coupled using DMF as solvent, and DIPEA in DMF (7% v/v) with 
HCTU (3 eq.) as the activating agent for 50 min.  
Protected peptide-resins were cleaved by treating with Reagent K (5 ml) composed of TFA-
H2O-thioanisole-phenol-EDT (82.5%:5%:5%:5%:2.5%) for 3 h. The cleavage mixture was 
filtered, concentrated by a stream of N2, precipitated in cold Et2O and centrifuged at 3000 
rpm for 5 min. The crude product was dissolved in water-acetonitrile mixture (50%:50%) and 
lyophilised. 
(2S,7S)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((S,S)-1)  
The linear peptide chain was prepared by the general method described above on Rink resin 
(0.05 meq). The peptide resin was treated with (2S,7S)-N,N-di-Boc-diaminosuberic acid, 
(S,S)-5 (10.0 mg, 0.5 eq.), PyClock (110 mg, 4 eq.), DIPEA (87.0 µl, 10 eq.) in DMF (5 ml) 
overnight. After cleavage and purification, the peptide was lyophilized to yield a white fluffy 
solid (3.5 mg). HPLC RT 11.21 min. ESI-MS: 569.75 (M+3H)3+. HRMS (ESI) m/z 
calculated for [C80H124N26O16+2H]
2+, 853.4923, found: 853.4947.  
(2R,7R)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((R,R)-1)  
The (R,R) diastereomer of I was prepared in the same fashion as the (S,S)-diastereomer, but on 
0.05 mmol scale, and using (R,R)-5 yielding a fluffy white sold (13.4 mg). HPLC RT 11.16 
min. ESI-MS: 569.85 (M+3H)3+. HRMS (ESI) m/z calculated for [C80H124N26O16+3H]
3+ 
569.6660, found: 569.6683. 
Alternatively, peptide (R,R)-9  (16 mg) (see below) was dissolved in EtOAc (10 ml) then 
cycled through an H-Cube™ incorporating a 10% Pd/C cartridge at 50˚C at 1.5 ml/min under 
H2 (50 psi). After 1h the solvent was removed in vacuo and the residue was purified by 
HPLC to yield a white fluffy solid (9.2 mg).  
(2S,7S)-Diaminooct-4-enedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((S,S)-9)  
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The Fmoc protected linear peptide, Fmoc-Gly(All)-Tyr(OtBu)-Arg(Pbf)-Leu-Arg(Pbf)-
Tyr(OtBu)-Rink amide resin was treated with LiCl in DMF (4.2 mg/ml, 200 µl), Grubbs 
catalyst 2nd generation (0.2 eq.) and DCM (4.5 ml) in a glass microwave vessel. The mixture 
was charged with N2 and heated in a microwave reactor at 100˚C for 3 h. After the solvent 
was removed by filtration, Fmoc deprotection was performed using 20% v/v piperidine in 
DMF (5 ml) for 2×5 min, and the peptide was cleaved off resin as described above, to yield a 
white fluffy solid (10.0 mg), HPLC RT 11.19 min. ESI-MS: 569.05 (M+3H)3+. HRMS (ESI) 
m/z calculated for [C80H122N26O16+2Η]
2+ 852.9881.  
(2R,7R)-Diaminooct-4-enedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((R,R)-9)  
The peptide was prepared as for (S,S)-9 above, but utilizing Fmoc-D-Gly(All) to yield a white 
fluffy solid (5.1 mg), HPLC RT 11.34 min. ESI-MS: 569.10 (M+3H)3+. 
(2S,7S)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr dimethyl ester) ((S,S)-12)  
A mixture of Fmoc-Tyr-OMe, 10 (2 eq.) and DIPEA (6 eq.) in DCM (5 ml) was added to 2-
chlorotrityl resin and agitated overnight. The resin was filtered, washed with DCM×3, 
MeOH×1 and Et2O×1, and dried in vacuo. The derivatised resin was subject to standard solid 
phase synthesis as described above and treated with (2S,7S)-5 as described for (S,S)-1 above. 
After cleavage and purification, the peptide was lyophilized to yield a white fluffy solid (40.5 
mg). HPLC RT 12.06 min. ESI-MS: 579.85 (M+3H)3+. HRMS (ESI) m/z calculated for 
[C82H126N24O18+2Η]
2+ 868.4914, found: 868.4956. 
 (2S,7S)-Diaminooctanedioyl-(Tyr-Arg-Leu-Arg-Tyr methyl ester) (Tyr-Arg-Leu-Arg-Tyr 
amide) ((S,S)-13)  
(S,S)-13 was prepared as for (S,S)-12  above, except that the 2-chlorotrityl chloride resin was 
treated with a 50%:50% mixture of Fmoc-Tyr-OMe (10) and Fmoc-Tyr-NH2 (11). After 
cleavage and purification, the peptide was lyophilized to yield a white fluffy solid (7.5 mg). 
HPLC RT 11.61 min. ESI-MS: 574.85 (M+3H)3+. Side products of (S,S)-1 and (S,S)-12 were 
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also identified in the product mixture. HRMS (ESI) m/z calculated for [C81H125N25O17+2Η]
2+ 
860.9920 found: 860.9956. 
Fluorescent labelling of peptides 
Peptides were treated with a mixture of the labelling agent (sCy5 or RhB, see Figure 2) (0.7 
eq.), PyClock (2 eq.) and NMM (12 eq.) in DMF (2 ml). The mixture was stirred in darkness 
overnight and DMF was removed in vacuo. The crude product was washed with TFA (1 ml), 
precipitated with cold Et2O and centrifuged at 3000 rpm for 5 min. The resulting precipitate 
was dissolved in water-acetonitrile (50%:50%) and lyophilised.  
Mono-sCy5-(2S,7S)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((S,S)-14)  
According to the general method for fluorescent labelling described above, (S,S)-1 (10 mg) 
was treated with sCy5-OH (0.7 eq.). After purification, (S,S)-14 was obtained as a fluffy blue 
powder (1.3 mg). HPLC RT 12.38 min. ESI-MS: 782.70 (M+3H)3+. 
Mono-sCy5-(2R,7R)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((R,R)-14) 
According to the general method for fluorescent labelling described above, (R,R)-1, (5.9 mg) 
was treated with sCy5-OH (0.7 eq.). After purification, (R,R)-14 was obtained as a fluffy blue 
powder (1.2 mg). HPLC RT 12.36 min. ESI-MS: 782.75 (M+3H)3+. 
Mono-RhB-(2S,7S)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((S,S)-15)  
According to the general method for fluorescent labelling described above, (S,S)-1, (10 mg) 
was treated with RhB-OH (0.7 eq.). After purification, (S,S)-15 was obtained as a fluffy magenta 
powder (0.5 mg). HPLC RT 13.37 min. ESI-MS: 767.40 (M+3H)3+. 
Mono-RhB-(2S,7S)-Diaminooct-4-enedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((S,S)-16)  
According to the general method for fluorescent labelling described above, (S,S)-9, (10 mg) 
was treated with RhB-OH (0.7 eq.). After purification, (S,S)-16 was obtained as a fluffy magenta 
powder (1.2 mg). HPLC RT 13.36 min. ESI-MS: 766.65 (M+3H)3+. 
Mono-RhB-(2R,7R)-Diaminooct-4-enedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((R,R)-16)  
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According to the general method for fluorescent labelling described above, (R,R)-9, (10 mg) 
was treated with RhB-OH (0.7 eq.). After purification, (R,R)-16 was obtained as a fluffy magenta 
powder (1.4 mg). HPLC RT 13.26 min. ESI-MS: 766.70 (M+3H)3+. 
Cell culture 
HEK293T and 293TR cells (Invitrogen) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine serum, and passaged 
when confluent by trypsinisation (0.25% w/v in Versene). Mixed population 293TR cell lines 
inducibly expressing Y receptors tagged with C-terminal GFP, and dual stable HEK293 cell 
lines expressing Y receptor-Yc and β-arrestin2-Yn (where Yc and Yn are complementary 
fragments of YFP) are as previously reported.35, 39, 40 
Y4R competition binding and imaging assays 
293TR Y4-GFP or Y1-GFP cells were seeded at 20,000 cells / well in poly-D-lysine coated 
96-well imaging plates (Greiner 655090), treated as required with 1 µg/ml tetracycline for 
18-21 h and then used in experiments at confluence. Incubations were performed in HEPES-
buffered saline solution (HBSS) including 0.1% BSA, the permeable nuclear dye H33342 (2 
µg/ml, Sigma) and varying concentrations of competitor ligands (10-10 M to 10-5 M) for 2 
min, prior to the addition of fluorescent ligand at the concentration indicated. After 30 min at 
37°C the media was replaced with HBSS / 0.1% BSA and plates were immediately imaged (2 
sites / well) on an IX Ultra confocal platereader (Molecular Devices, Sunnyvale CA, U.S.A.) 
using laser excitation / emission filter settings appropriate for H33342 (DAPI), Y receptor-
GFP (FITC), and sCy5-labelled peptides. Bound ligand fluorescence was quantified by 
granularity analysis (2-3 µm diameter granules; MetaXpress 5.3, Molecular Devices), and 
normalised to positive (totals 100 %) and negative (0%, in presence of 100 nM PP) controls. 
pIC50 values were then determined from the pooled data using GraphPad Prism v6 (GraphPad 
software, San Diego, CA). 
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Y4R-β-arrestin recruitment assays 
Bimolecular fluorescence complementation (BiFC) based detection of Y receptor-β-arrestin2 
association was performed as described previously.39, 40 The Y4R arrestin BiFC cell lines 
were seeded at 40,000 cells / well onto poly-D-lysine coated Greiner 655090 imaging plates, 
and experiments performed 24 h later. Stimulation with human PP (Bachem, St. Helens, 
U.K.) or other ligands was performed in HBSS / 0.1% BSA (10-10 M-10-6 M, duplicate wells) 
for 60 min at 37°C. Incubations were terminated by fixation with 3% paraformaldehyde in 
phosphate buffered saline (PBS, 10 min at 21°C), the cells were washed once with PBS and 
the cell nuclei were stained for 15 min with H33342 (2 µg ml-1 in PBS, Sigma).  H33342 was 
then removed by a final PBS wash. Images (4 central sites / well) were acquired 
automatically on the IX Ultra confocal platereader, using 405 nm / 488 nm laser lines for 
H33342 and complemented YFP excitation respectively. 
A granularity algorithm (MetaXpress 5.3) identified internal fluorescent compartments within 
these images of at least 3 µm diameter (range set to 3-1 µm), on the basis of granule intensity 
thresholds set with reference to the vehicle or 100 nM PP plate controls. The response for 
each data point was quantified as mean granule average intensity / cell, normalised to the 
reference agonist response. Concentration response curves were fitted to the pooled data by 
non-linear least squares regression (GraphPad Prism), yielding estimates of agonist potency 
as pEC50 and maximum response (Rmax). 
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Abbreviations Used 
BiFC Bimolecular fluorescence complementation 
DCM dichloromethane 
DIPEA N,N-diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DMF N,N-dimethylformamide 
EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDT 1,2-ethanedithiol 
EtOAc ethyl acetate 
GFP green fluorescent protein 
HCTU O-(6-chlorobenzotriazol-1-yl)-N,N,N,N-tetramethyluronium 
hexafluorophosphate 
MeOH  methanol 
NMM  N-methylmorpholine 
Pd/C  palladium on activated carbon 
PyClock (6-Chlorobenzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate 
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